Adagio Medical Holdings (ADGM) Research & Development (2023 - 2026)

Adagio Medical Holdings has disclosed Research & Development across 4 years of filings, most recently posting $2.4 million for Q2 2026.

• In Q2 2026, Research & Development rose 24.3% year-over-year to $2.4 million; the TTM figure through Jun 2026 stood at $10.2 million (up 5.02% YoY), while the FY2025 annual figure was $10.6 million, up 129.59% from the prior year.
• Research & Development came in at $2.4 million for Q2 2026 at Adagio Medical Holdings, down from $2.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $4.4 million in Q3 2023 to a low of $1.2 million in Q3 2024.
• Average Research & Development over 4 years is $2.7 million, with a median of $2.7 million recorded in 2026.
• Year-over-year, Research & Development plunged 72.45% in 2024 and surged 127.94% in 2025.
• Over 4 years, Research & Development stood at $1.8 million in 2023, then plunged by 31.4% to $1.2 million in 2024, then surged by 83.65% to $2.2 million in 2025, then rose by 9.62% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $2.4 million in Q2 2026, $2.7 million in Q1 2026, and $2.2 million in Q4 2025.